成大生物：冻干人用狂犬病疫苗获得药品注册证书

Core Viewpoint - The company announced that its wholly-owned subsidiary has received a drug registration certificate for a lyophilized human rabies vaccine from the National Medical Products Administration, marking a significant advancement in vaccine development in China [1] Group 1: Product Details - The vaccine utilizes the MRC-5 human diploid cell line recommended by the World Health Organization, demonstrating excellent safety, immunogenicity, and durability of immunity, particularly suitable for immunocompromised populations such as allergy sufferers, the elderly, and children [1] - This product is the first in China to cover three immunization schedules: "simplified 4-dose," "2-1-1," and "5-dose" regimens, showcasing its versatility in immunization protocols [1] Group 2: Regulatory Approval - The approval of the "simplified 4-dose" immunization schedule signifies a new breakthrough in the adaptability of human diploid cell rabies vaccines in China [1]